Target Price | $805.19 |
Price | $527.78 |
Potential | 52.56% |
Number of Estimates | 21 |
21 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $805.19. This is 52.56% higher than the current stock price. The highest price target is $979.00 85.49% , the lowest is $535.00 1.37% . | |
A rating was issued by 27 analysts: 20 Analysts recommend Regeneron Pharmaceuticals to buy, 5 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 52.56% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
22 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.4b . This is 4.89% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.4b 2.35% , the lowest is $12.6b 10.57% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $13.4b | 5.67% |
2026 | $14.3b | 6.70% |
2027 | $15.8b | 10.65% |
2028 | $16.9b | 7.10% |
2029 | $18.2b | 7.39% |
9 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.3b . This is 2.62% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.3b 18.35% , the lowest is $3.6b 19.66% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 2.37% |
---|---|---|
2025 | $4.3b | 6.83% |
2026 | $5.0b | 14.39% |
2027 | $5.9b | 19.56% |
2028 | $6.4b | 7.09% |
2029 | $7.2b | 13.17% |
2024 | 32.79% | 9.82% |
---|---|---|
2025 | 32.39% | 1.22% |
2026 | 34.72% | 7.19% |
2027 | 37.52% | 8.06% |
2028 | 37.52% | 0.00% |
2029 | 39.53% | 5.36% |
11 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.3b . This is 22.43% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.1b 3.00% , the lowest is $2.5b 41.26% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 10.27% |
---|---|---|
2025 | $3.3b | 20.51% |
2026 | $3.7b | 11.67% |
2027 | $4.5b | 22.11% |
2028 | $5.1b | 13.73% |
2029 | $5.6b | 10.14% |
2024 | 29.21% | 1.84% |
---|---|---|
2025 | 24.61% | 15.75% |
2026 | 25.76% | 4.67% |
2027 | 28.43% | 10.36% |
2028 | 30.19% | 6.19% |
2029 | 30.96% | 2.55% |
11 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $30.48 . This is 22.42% lower than earnings per share in the financial year 2024. The highest EPS forecast is $38.11 3.00% , the lowest is $23.08 41.26% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $30.48 | 20.50% |
2026 | $34.03 | 11.65% |
2027 | $41.56 | 22.13% |
2028 | $47.26 | 13.72% |
2029 | $52.06 | 10.16% |
Current | 13.43 | 52.49% |
---|---|---|
2025 | 17.32 | 28.97% |
2026 | 15.51 | 10.45% |
2027 | 12.70 | 18.12% |
2028 | 11.17 | 12.05% |
2029 | 10.14 | 9.22% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.83 and an P/S ratio of 4.25 .
This results in the following potential growth metrics and future valuations:
Current | 3.64 | 51.14% |
---|---|---|
2025 | 3.83 | 5.28% |
2026 | 3.59 | 6.28% |
2027 | 3.25 | 9.62% |
2028 | 3.03 | 6.63% |
2029 | 2.82 | 6.89% |
Current | 4.05 | 49.73% |
---|---|---|
2025 | 4.25 | 5.14% |
2026 | 3.99 | 6.28% |
2027 | 3.60 | 9.63% |
2028 | 3.36 | 6.63% |
2029 | 3.13 | 6.89% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Buy
➜
Buy
|
Unchanged | May 01 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Apr 30 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 30 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Guggenheim:
Buy
➜
Buy
|
May 01 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Apr 30 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Apr 30 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 30 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Apr 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.